Roche Veteran Khwaja Named Voyager Therapeutics Chief Medical Officer

Xconomy Boston — 

Omar Khwaja has been appointed chief medical officer of Voyager Therapeutics (NASDAQ: VYGR). Khwaja comes to the Cambridge, MA-based gene therapy developer from Roche, where he was most recently global head of neuroscience translational medicine and global head of rare diseases. Voyager’s lead drug, VY-AADC, is in mid-stage studies testing it in advanced Parkinson’s disease.